Peak Patent Exposure Offers Opportunity
Novartis pays a generous 3.6% dividend yield & is a well diversified healthcare firm.
Novartis maintains an impressive pipeline of new drugs. Novartis AG (NYSE:NVS) is a large pharmaceutical firm based in Switzerland. Its shares trade on the NYSE as an American Depository Receipt, or ADR. The company was created by the merger of Sandoz AG and Ciba-Geigy AG in December 1996. It is primarily a pharmaceutical company, but also is a major producer of generic drugs through its Sandoz division. It offers eye care products through its Alcon division and also sells consumer and animal health products. Pharmaceutical products account for 55% of sales, generics for 16%, and eye care for 19%.
My positive investment thesis for Novartis is based upon six key criteria, which include:
- Large market capitalization.
- A leadership position within an industry.
- A strong balance sheet & solid cash flow.
Click on link to read further on this exclusive article on Top 100 stock Novartis: